Patent number: 10112955
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
October 30, 2018
Assignee:
eFFECTOR Therapeutics, Inc.
Inventors:
Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E. Webber, Mike Shaghafi, Douglas Murphy, Chinh Tran